Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease.

@article{Swaminath2013CosteffectivenessOQ,
  title={Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease.},
  author={A Swaminath and Nahid Bhadelia and Y. Claire Wang},
  journal={Inflammatory bowel diseases},
  year={2013},
  volume={19 11},
  pages={
          2444-9
        }
}
BACKGROUND Anti-tumor necrosis factor α drugs are known to reactivate latent tuberculosis (TB). Current guidelines recommend screening for latent tuberculosis infection, with either tuberculin skin test (TST) or interferon gamma release assays such as QuantiFERON-TB Gold (QFT-G). Given the high rates of anergy to TST among immunosuppressed inflammatory bowel disease (IBD) patients, there is considerable interest in evaluating the superiority of interferon gamma release assays over TST in this… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations

Similar Papers

Loading similar papers…